alendronate has been researched along with Breast Cancer in 65 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To considerably enhance treatment efficacy for bone metastatic breast cancer via dual bone/tumor-targeted chemotherapy, a nanoparticle-based delivery system comprising poly(lactic-co-glycolic acid) (PLGA) as the hydrophobic core coated with alendronate-modified d-α-tocopheryl polyethylene glycol succinate (ALN-TPGS) and folic acid-conjugated TPGS (FA-TPGS) was developed as a vehicle for paclitaxel (PTX) in this work." | 7.96 | Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer. ( Chen, HH; Chen, SH; Chiang, WH; Chiu, HC; Chuang, CL; Liu, TI, 2020) |
| "In this retrospective study, 90 postmenopausal women with early breast cancer who were being treated with both AI and alendronate 70 mg weekly (ALN + AI), and 90 age- and body mass index (BMI)-matched patients who were only taking alendronate (ALN-only) were analyzed." | 7.96 | Aromatase inhibitors attenuate the effect of alendronate in women with breast cancer. ( Kim, JH; Kim, SW; Kong, SH; Shin, CS, 2020) |
| " Here we demonstrate the divergent roles of ATP and adenosine released by bone osteocytes on breast cancers." | 7.81 | Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis. ( Ellies, LG; Gao, X; Jiang, JX; Riquelme, MA; Sun, LZ; Zhou, JZ, 2015) |
| "Paclitaxel (PTX) and alendronate (ALN) are effective drugs used for the treatment of breast cancer bone metastases." | 7.79 | Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases. ( Barshack, I; Benayoun, L; Clementi, C; Eldar-Boock, A; Miller, K; Pasut, G; Polyak, D; Satchi-Fainaro, R; Shaked, Y, 2013) |
| "Controversy still exists regarding whether alendronate (ALN) use increases the risk of esophageal cancer or breast cancer." | 7.78 | A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study. ( Chang, SN; Kao, CH; Lee, WY; Liang, JA; Lin, MC; Muo, CH; Sun, LM; Sung, FC, 2012) |
| " However, the effect of oral alendronate treatment on clinical and pathological properties of breast cancer has not been reported." | 7.78 | Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use. ( Aksoy, S; Altundağ, K; Arık, Z; Özdemir, NY; Sendur, MA; Yaman, S; Zengin, N, 2012) |
| "Hazard ratio for incident breast cancer in the bisphosphonate treatment group compared to the placebo group." | 6.79 | Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. ( Barrett-Connor, E; Bauer, DC; Black, DM; Cauley, JA; Cummings, SR; Ensrud, KE; Hue, TF, 2014) |
| " To determine whether a lower dosage in oral form combined with calcitriol can effectively manage AI-induced bone loss, we performed a randomized, double-blind, prospective, placebo-controlled 24-week trial with a combination of alendronate and 0." | 6.78 | Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study. ( Lim, SK; Park, BW; Park, HS; Park, S; Rhee, Y; Song, K, 2013) |
| "Although the prognosis of patients with breast cancer continues to improve, breast cancer metastasis to bones remains high in incidence and challenging to manage." | 5.51 | Alendronate-Modified Polymeric Micelles for the Treatment of Breast Cancer Bone Metastasis. ( Bronich, TK; Cohen, SM; Hyun, MA; Liu, T; Romanova, S; Singh, RK; Wang, S; Zhang, C, 2019) |
| "Many cancers, such as human breast cancer and lung cancer, easily metastasize to bones, leading to the formation of secondary tumors in advanced stages." | 5.48 | In Vivo Evaluation of Reduction-Responsive Alendronate-Hyaluronan-Curcumin Polymer-Drug Conjugates for Targeted Therapy of Bone Metastatic Breast Cancer. ( Chen, D; Dong, X; Guo, C; Liu, W; Wang, B; Wang, K; Yu, Y, 2018) |
| "Postmenopausal women with breast cancer were randomly assigned to receive alendronate or placebo for 1 year within 3 months after withdrawal of tamoxifen therapy." | 5.13 | Prevention of bone loss after withdrawal of tamoxifen. ( Brown, IN; Cohen, A; Fleischer, JB; Hershman, DL; Joe, AK; Johnson, MK; McMahon, DJ; Silverberg, SJ, 2008) |
| "In this retrospective study, 90 postmenopausal women with early breast cancer who were being treated with both AI and alendronate 70 mg weekly (ALN + AI), and 90 age- and body mass index (BMI)-matched patients who were only taking alendronate (ALN-only) were analyzed." | 3.96 | Aromatase inhibitors attenuate the effect of alendronate in women with breast cancer. ( Kim, JH; Kim, SW; Kong, SH; Shin, CS, 2020) |
| "To considerably enhance treatment efficacy for bone metastatic breast cancer via dual bone/tumor-targeted chemotherapy, a nanoparticle-based delivery system comprising poly(lactic-co-glycolic acid) (PLGA) as the hydrophobic core coated with alendronate-modified d-α-tocopheryl polyethylene glycol succinate (ALN-TPGS) and folic acid-conjugated TPGS (FA-TPGS) was developed as a vehicle for paclitaxel (PTX) in this work." | 3.96 | Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer. ( Chen, HH; Chen, SH; Chiang, WH; Chiu, HC; Chuang, CL; Liu, TI, 2020) |
| "Combined therapy with BJD and alendronate can act synergistically against osteoporosis, which was possibly related to a reduced bone conversion rate through inhibiting bone resorption." | 3.85 | Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment. ( Guo, W; Huang, XH; Liang, RH; Su, L; Wang, CJ, 2017) |
| " Here we demonstrate the divergent roles of ATP and adenosine released by bone osteocytes on breast cancers." | 3.81 | Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis. ( Ellies, LG; Gao, X; Jiang, JX; Riquelme, MA; Sun, LZ; Zhou, JZ, 2015) |
| "Paclitaxel (PTX) and alendronate (ALN) are effective drugs used for the treatment of breast cancer bone metastases." | 3.79 | Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases. ( Barshack, I; Benayoun, L; Clementi, C; Eldar-Boock, A; Miller, K; Pasut, G; Polyak, D; Satchi-Fainaro, R; Shaked, Y, 2013) |
| "Patients treated with alendronate and raloxifene had similar adjusted fracture rates in up to 8 years of adherent treatment, and raloxifene patients had lower breast cancer rates." | 3.79 | Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. ( Burge, R; Chu, BC; Curkendall, S; Diakun, DR; Foster, SA; Krege, JH; Shi, N; Stock, J, 2013) |
| "Controversy still exists regarding whether alendronate (ALN) use increases the risk of esophageal cancer or breast cancer." | 3.78 | A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study. ( Chang, SN; Kao, CH; Lee, WY; Liang, JA; Lin, MC; Muo, CH; Sun, LM; Sung, FC, 2012) |
| " However, the effect of oral alendronate treatment on clinical and pathological properties of breast cancer has not been reported." | 3.78 | Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use. ( Aksoy, S; Altundağ, K; Arık, Z; Özdemir, NY; Sendur, MA; Yaman, S; Zengin, N, 2012) |
| "At 10(-5) M, amino-bisphosphonates (alendronate and pamidronate) inhibited breast cancer cell viability and induced a significant decrease in hTERT gene expression with respect to controls (82% and 71% in MCF-7 cells; 74% and 60% in T47D, p<0." | 3.74 | Amino-bisphosphonates decrease hTERT gene expression in breast cancer in vitro. ( Azzarello, G; Balducci, E; Bertoldo, F; Dalle Carbonare, L; Fracalossi, A; Lo Cascio, V; Valenti, MT; Vinante, O, 2007) |
| " In this study we used a standardized ATP-based tumor chemosensitivity assay (ATP-TCA) to measure the activity of alendronate, clodronate and zoledronic acid in five ovarian carcinoma cell lines and human solid tumors (breast, lung, ovarian, unknown primary carcinoma, and cutaneous and uveal melanoma) (n=34)." | 3.73 | Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay. ( Conroy, M; Cree, IA; Fernando, A; Knight, LA; Kurbacher, CM; Polak, M, 2005) |
| " We studied the direct effects of clodronate, alendronate, and pamidronate (from 10(-6) to 10(-4) M) on MCF-7 human breast cancer cell line." | 3.73 | Bisphosphonates decrease telomerase activity and hTERT expression in MCF-7 breast cancer cells. ( Azzarello, G; Balducci, E; Crepaldi, G; Dalle Carbonare, L; Giannini, S; Realdi, G; Valenti, MT; Vinante, O, 2005) |
| "Treatment with alendronate was associated with significantly greater improvements in lumbar spine BMD within one year in breast cancer survivors when compared with treatment with cyclic etidronate or calcium and vitamin D." | 3.73 | Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis? ( Adachi, JD; Boulos, P; Brown, JP; Goldsmith, CH; Hanley, DA; Ioannidis, G; Josse, RG; Kouroukis, T; Murray, TM; Olszynski, WP; Papaioannou, A; Petrie, A; Sawka, AM; Sebaldt, RJ; Tenenhouse, A; Thabane, L, 2005) |
| "To investigate the safety of rapid infusion of alendronate, we used alendronate therapy for 11 breast cancer patients with bone metastasis." | 3.70 | [A study of the safety of rapid infusion of alendronate]. ( Kokawa, Y; Oura, S; Sakurai, T; Tamaki, T; Umemura, T; Yoshimura, G, 1999) |
| "Hormone replacement therapy, alendronate therapy, and raloxifene therapy have similar predicted efficacies in preventing hip fractures (estimated relative risk, 0." | 3.70 | Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. ( Col, NF; Eckman, MH; Goldberg, RJ; Orr, RK; Pauker, SG; Ross, EM; Wong, JB, 1999) |
| "Hazard ratio for incident breast cancer in the bisphosphonate treatment group compared to the placebo group." | 2.79 | Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. ( Barrett-Connor, E; Bauer, DC; Black, DM; Cauley, JA; Cummings, SR; Ensrud, KE; Hue, TF, 2014) |
| " To determine whether a lower dosage in oral form combined with calcitriol can effectively manage AI-induced bone loss, we performed a randomized, double-blind, prospective, placebo-controlled 24-week trial with a combination of alendronate and 0." | 2.78 | Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study. ( Lim, SK; Park, BW; Park, HS; Park, S; Rhee, Y; Song, K, 2013) |
| "Dermatomyositis is an inflammatory autoimmune condition that has also been associated with malignancy." | 2.47 | Multicentric reticulohistiocytosis with dermatomyositis-like features: a more common disease presentation than previously thought. ( Fett, N; Liu, RH, 2011) |
| " Although newer bisphosphonates are more potent, oral bioavailability remains < 1%." | 2.41 | Oral bisphosphonates: A review of clinical use in patients with bone metastases. ( Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000) |
| "Alendronate has the greatest positive effect on BMD and reduces the incidence of vertebral and nonvertebral fractures." | 2.41 | Prevention and treatment of osteoporosis in women with breast cancer. ( Mincey, BA; Moraghan, TJ; Perez, EA, 2000) |
| "Although the prognosis of patients with breast cancer continues to improve, breast cancer metastasis to bones remains high in incidence and challenging to manage." | 1.51 | Alendronate-Modified Polymeric Micelles for the Treatment of Breast Cancer Bone Metastasis. ( Bronich, TK; Cohen, SM; Hyun, MA; Liu, T; Romanova, S; Singh, RK; Wang, S; Zhang, C, 2019) |
| "Many cancers, such as human breast cancer and lung cancer, easily metastasize to bones, leading to the formation of secondary tumors in advanced stages." | 1.48 | In Vivo Evaluation of Reduction-Responsive Alendronate-Hyaluronan-Curcumin Polymer-Drug Conjugates for Targeted Therapy of Bone Metastatic Breast Cancer. ( Chen, D; Dong, X; Guo, C; Liu, W; Wang, B; Wang, K; Yu, Y, 2018) |
| "A cell line-specific, dose-related cytotoxicity was observed for 5-FdU-ale in all cancer cell lines tested, which was significantly less toxic than 5-FdU alone when compared to the benign osteoblasts or stromal cells." | 1.42 | In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis. ( Busch, C; Noor, S; Schem, C; Schott, S; Tiwari, S; Tower, RJ; Vallet, S, 2015) |
| "Breast or prostate cancer patients were treated with zoledronate." | 1.39 | Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic. ( Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N, 2013) |
| "One-third of all breast cancers are present as clinically nonpalpable lesions." | 1.39 | Preclinical studies of the role of iron oxide magnetic nanoparticles for nonpalpable lesion localization in breast cancer. ( Ahmed, M; de Rosales, RT; Douek, M, 2013) |
| "Patients with symptoms of osteoporosis, prostate cancer, or breast cancer were surveyed to determine their knowledge of bisphosphonates." | 1.38 | Awareness and education of patients receiving bisphosphonates. ( Bauer, JS; Beck, N; Eitner, S; Kiefer, J; Stockmann, P; Wichmann, M, 2012) |
| "In vitro tests with breast cancer cells show that the γFe(2)O(3)@alendronate hybrid nanomaterial reduces cell viability and acts as a drug delivery system." | 1.37 | A multimodal magnetic resonance imaging nanoplatform for cancer theranostics. ( Benyettou, F; Chebbi, I; Di Benedetto, M; Lalatonne, Y; Lecouvey, M; Motte, L; Serfaty, JM, 2011) |
| "A total of 696 women with stage I-III breast cancer were included." | 1.36 | Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System. ( Abrams, J; Bhargaval, A; Graff, JJ; Nahleh, Z; Nirmal, K, 2010) |
| "Alendronate was the most frequently implicated (six cases) and risedronate (five cases)." | 1.36 | [Jaw osteonecrosis induced by oral biphosphonates: 12 cases]. ( Barrier, A; Descroix, V; Goudot, P; Lescaille, G; Rigolet, A; Ruhin, B, 2010) |
| " Twelve patients who presented with exposed bone associated with bisphosphonates were reviewed to determine the type, dosage and duration of their bisphosphonate therapy, presenting findings, comorbidities and the event that incited the bone exposure." | 1.34 | Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. ( Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E, 2007) |
| "For 55 and 60 year old women with osteopenia, treatment with raloxifene compares favorably to interventions accepted as cost-effective." | 1.34 | Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. ( Johnston, JA; Klein, R; Meadows, ES; Ohsfeldt, RL; Rousculp, MD; Smolen, L, 2007) |
| "Sixty-two (52." | 1.33 | Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. ( Broumand, V; Fortin, M; Marx, RE; Sawatari, Y, 2005) |
| "Many women now survive breast cancer, but find themselves at increased risk of menopausal complications." | 1.31 | Managing menopause after breast cancer: balancing risks and benefits. ( Moore, HC, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (12.31) | 18.2507 |
| 2000's | 23 (35.38) | 29.6817 |
| 2010's | 31 (47.69) | 24.3611 |
| 2020's | 3 (4.62) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SH | 1 |
| Liu, TI | 1 |
| Chuang, CL | 1 |
| Chen, HH | 1 |
| Chiang, WH | 1 |
| Chiu, HC | 1 |
| Kong, SH | 1 |
| Kim, JH | 1 |
| Kim, SW | 1 |
| Shin, CS | 1 |
| Wu, H | 1 |
| Luo, Y | 1 |
| Xu, D | 1 |
| Ke, X | 1 |
| Ci, T | 1 |
| He, Y | 1 |
| Huang, Y | 1 |
| Huang, Z | 1 |
| Jiang, Y | 1 |
| Sun, X | 1 |
| Shen, Y | 1 |
| Chu, W | 1 |
| Zhao, C | 1 |
| Ou, YJ | 1 |
| Chiu, HF | 1 |
| Wong, YH | 1 |
| Yang, CC | 1 |
| Yang, YH | 1 |
| Wang, K | 1 |
| Guo, C | 1 |
| Dong, X | 1 |
| Yu, Y | 1 |
| Wang, B | 1 |
| Liu, W | 1 |
| Chen, D | 1 |
| Zhu, J | 1 |
| Huo, Q | 1 |
| Xu, M | 1 |
| Yang, F | 1 |
| Li, Y | 1 |
| Shi, H | 1 |
| Niu, Y | 1 |
| Liu, Y | 1 |
| Liu, T | 1 |
| Romanova, S | 1 |
| Wang, S | 1 |
| Hyun, MA | 1 |
| Zhang, C | 1 |
| Cohen, SM | 1 |
| Singh, RK | 1 |
| Bronich, TK | 1 |
| Miller, K | 2 |
| Clementi, C | 1 |
| Polyak, D | 2 |
| Eldar-Boock, A | 2 |
| Benayoun, L | 2 |
| Barshack, I | 1 |
| Shaked, Y | 2 |
| Pasut, G | 1 |
| Satchi-Fainaro, R | 2 |
| Foster, SA | 1 |
| Shi, N | 1 |
| Curkendall, S | 1 |
| Stock, J | 1 |
| Chu, BC | 1 |
| Burge, R | 1 |
| Diakun, DR | 1 |
| Krege, JH | 1 |
| Ahmed, M | 1 |
| de Rosales, RT | 1 |
| Douek, M | 1 |
| Nomura, T | 1 |
| Shibahara, T | 1 |
| Uchiyama, T | 1 |
| Yamamoto, N | 1 |
| Shibui, T | 1 |
| Yakushiji, T | 1 |
| Watanabe, A | 1 |
| Muramatsu, K | 1 |
| Ogane, S | 1 |
| Murayama, M | 1 |
| Sekine, R | 1 |
| Nakata, E | 1 |
| Fujimoto, Y | 1 |
| Zhou, JZ | 1 |
| Riquelme, MA | 1 |
| Gao, X | 1 |
| Ellies, LG | 1 |
| Sun, LZ | 1 |
| Jiang, JX | 1 |
| Ross, JS | 1 |
| Hue, TF | 1 |
| Cummings, SR | 1 |
| Cauley, JA | 2 |
| Bauer, DC | 1 |
| Ensrud, KE | 1 |
| Barrett-Connor, E | 1 |
| Black, DM | 1 |
| Mathew, A | 1 |
| Brufsky, A | 1 |
| Schott, S | 2 |
| Vallet, S | 1 |
| Tower, RJ | 1 |
| Noor, S | 1 |
| Tiwari, S | 1 |
| Schem, C | 1 |
| Busch, C | 1 |
| Huang, XH | 1 |
| Liang, RH | 1 |
| Su, L | 1 |
| Guo, W | 1 |
| Wang, CJ | 1 |
| Bivi, N | 1 |
| Romanello, M | 1 |
| Harrison, R | 1 |
| Clarke, I | 1 |
| Hoyle, DC | 1 |
| Moro, L | 1 |
| Ortolani, F | 1 |
| Bonetti, A | 1 |
| Quadrifoglio, F | 1 |
| Tell, G | 1 |
| Delneri, D | 1 |
| Chlebowski, RT | 1 |
| Chen, Z | 1 |
| Anderson, G | 1 |
| Rodabough, RJ | 1 |
| McTiernan, A | 1 |
| Lane, DS | 1 |
| Manson, JE | 1 |
| Snetselaar, L | 1 |
| Yasmeen, S | 1 |
| O'Sullivan, MJ | 1 |
| Safford, M | 1 |
| Hendrix, SL | 1 |
| Wallace, RB | 1 |
| Barrier, A | 1 |
| Lescaille, G | 1 |
| Rigolet, A | 1 |
| Descroix, V | 1 |
| Goudot, P | 1 |
| Ruhin, B | 1 |
| Hussein, O | 1 |
| Tiedemann, K | 1 |
| Komarova, SV | 1 |
| Fedele, S | 1 |
| Porter, SR | 1 |
| D'Aiuto, F | 1 |
| Aljohani, S | 1 |
| Vescovi, P | 1 |
| Manfredi, M | 1 |
| Arduino, PG | 1 |
| Broccoletti, R | 1 |
| Musciotto, A | 1 |
| Di Fede, O | 1 |
| Lazarovici, TS | 1 |
| Campisi, G | 1 |
| Yarom, N | 1 |
| Nahleh, Z | 1 |
| Abrams, J | 1 |
| Bhargaval, A | 1 |
| Nirmal, K | 1 |
| Graff, JJ | 1 |
| Fett, N | 1 |
| Liu, RH | 1 |
| Benyettou, F | 1 |
| Lalatonne, Y | 1 |
| Chebbi, I | 1 |
| Di Benedetto, M | 1 |
| Serfaty, JM | 1 |
| Lecouvey, M | 1 |
| Motte, L | 1 |
| Segal, E | 1 |
| Wallwiener, M | 1 |
| Kootz, B | 1 |
| Seeger, H | 1 |
| Fehm, T | 1 |
| Neubauer, H | 1 |
| Bauer, JS | 1 |
| Beck, N | 1 |
| Kiefer, J | 1 |
| Stockmann, P | 1 |
| Wichmann, M | 1 |
| Eitner, S | 1 |
| Martins, MA | 1 |
| Martins, MD | 1 |
| Lascala, CA | 1 |
| Curi, MM | 1 |
| Migliorati, CA | 1 |
| Tenis, CA | 1 |
| Marques, MM | 1 |
| Sendur, MA | 1 |
| Aksoy, S | 1 |
| Yaman, S | 1 |
| Arık, Z | 1 |
| Özdemir, NY | 1 |
| Zengin, N | 1 |
| Altundağ, K | 2 |
| Freiberger, JJ | 1 |
| Padilla-Burgos, R | 1 |
| McGraw, T | 1 |
| Suliman, HB | 1 |
| Kraft, KH | 1 |
| Stolp, BW | 1 |
| Moon, RE | 1 |
| Piantadosi, CA | 1 |
| Thamake, SI | 1 |
| Raut, SL | 1 |
| Gryczynski, Z | 1 |
| Ranjan, AP | 1 |
| Vishwanatha, JK | 1 |
| Rhee, Y | 1 |
| Song, K | 1 |
| Park, S | 1 |
| Park, HS | 1 |
| Lim, SK | 1 |
| Park, BW | 1 |
| Lee, WY | 1 |
| Sun, LM | 1 |
| Lin, MC | 1 |
| Liang, JA | 1 |
| Chang, SN | 1 |
| Sung, FC | 1 |
| Muo, CH | 1 |
| Kao, CH | 1 |
| Tosteson, AN | 1 |
| Grove, MR | 1 |
| Hammond, CS | 1 |
| Moncur, MM | 1 |
| Ray, GT | 1 |
| Hebert, GM | 1 |
| Pressman, AR | 1 |
| Ettinger, B | 1 |
| Waltman, NL | 1 |
| Twiss, JJ | 1 |
| Ott, CD | 1 |
| Gross, GJ | 1 |
| Lindsey, AM | 1 |
| Moore, TE | 1 |
| Berg, K | 1 |
| Hershman, D | 1 |
| Narayanan, R | 1 |
| Dalle Carbonare, L | 2 |
| Valenti, MT | 2 |
| Azzarello, G | 2 |
| Balducci, E | 2 |
| Crepaldi, G | 1 |
| Realdi, G | 1 |
| Vinante, O | 2 |
| Giannini, S | 1 |
| Knight, LA | 1 |
| Conroy, M | 1 |
| Fernando, A | 1 |
| Polak, M | 1 |
| Kurbacher, CM | 1 |
| Cree, IA | 1 |
| Marx, RE | 1 |
| Sawatari, Y | 1 |
| Fortin, M | 1 |
| Broumand, V | 1 |
| Sawka, AM | 1 |
| Ioannidis, G | 1 |
| Papaioannou, A | 1 |
| Thabane, L | 1 |
| Olszynski, WP | 1 |
| Brown, JP | 1 |
| Hanley, DA | 1 |
| Murray, TM | 1 |
| Josse, RG | 1 |
| Sebaldt, RJ | 1 |
| Petrie, A | 1 |
| Tenenhouse, A | 1 |
| Goldsmith, CH | 1 |
| Boulos, P | 1 |
| Kouroukis, T | 1 |
| Adachi, JD | 1 |
| Verdijk, R | 1 |
| Franke, HR | 1 |
| Wolbers, F | 1 |
| Vermes, I | 1 |
| Ozen, M | 1 |
| Karaahmet, F | 1 |
| Aydin, K | 1 |
| Sarici, F | 1 |
| Nastro, E | 1 |
| Musolino, C | 1 |
| Allegra, A | 1 |
| Oteri, G | 1 |
| Cicciù, M | 1 |
| Alonci, A | 1 |
| Quartarone, E | 1 |
| Alati, C | 1 |
| De Ponte, FS | 1 |
| Meadows, ES | 1 |
| Klein, R | 1 |
| Rousculp, MD | 1 |
| Smolen, L | 1 |
| Ohsfeldt, RL | 1 |
| Johnston, JA | 1 |
| Bertoldo, F | 1 |
| Fracalossi, A | 1 |
| Lo Cascio, V | 1 |
| Kuehn, BM | 1 |
| Pritchard, KI | 1 |
| Malden, NJ | 1 |
| Pai, AY | 1 |
| Cohen, A | 1 |
| Fleischer, JB | 1 |
| Johnson, MK | 1 |
| Brown, IN | 1 |
| Joe, AK | 1 |
| Hershman, DL | 1 |
| McMahon, DJ | 1 |
| Silverberg, SJ | 1 |
| Body, JJ | 1 |
| Coleman, RE | 1 |
| Piccart, M | 1 |
| Lappe, JM | 1 |
| Tinley, ST | 1 |
| Phillips, E | 1 |
| Knowles, S | 1 |
| Weber, E | 1 |
| Shear, NH | 1 |
| Oura, S | 3 |
| Sakurai, T | 3 |
| Yoshimura, G | 3 |
| Tamaki, T | 3 |
| Umemura, T | 3 |
| Kokawa, Y | 3 |
| Col, NF | 1 |
| Pauker, SG | 1 |
| Goldberg, RJ | 1 |
| Eckman, MH | 1 |
| Orr, RK | 1 |
| Ross, EM | 1 |
| Wong, JB | 1 |
| Major, PP | 1 |
| Lipton, A | 1 |
| Berenson, J | 1 |
| Hortobagyi, G | 1 |
| Naito, Y | 1 |
| Mincey, BA | 1 |
| Moraghan, TJ | 1 |
| Perez, EA | 1 |
| Moore, HC | 1 |
| Grady, D | 1 |
| Warrell, RP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| HORIZON-PFT: Pivotal Fracture Trial[NCT00049829] | Phase 3 | 7,700 participants | Interventional | 2002-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for alendronate and Breast Cancer
| Article | Year |
|---|---|
Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonate | 2017 |
Multicentric reticulohistiocytosis with dermatomyositis-like features: a more common disease presentation than previously thought.
Topics: Alendronate; Antineoplastic Protocols; Arthritis; Breast Neoplasms; Combined Modality Therapy; Derma | 2011 |
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation | 2004 |
Use of bisphosphonates in cancer patients.
Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid | 1996 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasm | 2000 |
Prevention and treatment of osteoporosis in women with breast cancer.
Topics: Aged; Alendronate; Bone Density; Breast Neoplasms; Calcitonin; Diphosphonates; Female; Fractures, Bo | 2000 |
Hypercalcemia and bone metastases in breast cancer.
Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hyper | 1990 |
5 trials available for alendronate and Breast Cancer
| Article | Year |
|---|---|
Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neopl | 2014 |
What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics.
Topics: Aged; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone D | 2012 |
Efficacy of a combined alendronate and calcitriol agent (Maxmarvil®) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study.
Topics: Alendronate; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers; Bone and Bones; Bone Density; | 2013 |
Prevention of bone loss after withdrawal of tamoxifen.
Topics: Absorptiometry, Photon; Administration, Oral; Alendronate; Alkaline Phosphatase; Bone Density; Bone | 2008 |
Hypercalcemia and bone metastases in breast cancer.
Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hyper | 1990 |
54 other studies available for alendronate and Breast Cancer
| Article | Year |
|---|---|
Alendronate/folic acid-decorated polymeric nanoparticles for hierarchically targetable chemotherapy against bone metastatic breast cancer.
Topics: Alendronate; Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Cell Line | 2020 |
Aromatase inhibitors attenuate the effect of alendronate in women with breast cancer.
Topics: Alendronate; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Remodeling; | 2020 |
Low molecular weight heparin modified bone targeting liposomes for orthotopic osteosarcoma and breast cancer bone metastatic tumors.
Topics: Alendronate; Animals; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prolif | 2020 |
Bisphosphonate-functionalized coordination polymer nanoparticles for the treatment of bone metastatic breast cancer.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cel | 2017 |
In Vivo Evaluation of Reduction-Responsive Alendronate-Hyaluronan-Curcumin Polymer-Drug Conjugates for Targeted Therapy of Bone Metastatic Breast Cancer.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cur | 2018 |
Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone Neoplasms; Bortezomib; Breast Neoplasms; Catechols | 2018 |
Alendronate-Modified Polymeric Micelles for the Treatment of Breast Cancer Bone Metastasis.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breas | 2019 |
Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases.
Topics: Alendronate; Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Line, | 2013 |
Fractures in women treated with raloxifene or alendronate: a retrospective database analysis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Cohort Studies; | 2013 |
Preclinical studies of the role of iron oxide magnetic nanoparticles for nonpalpable lesion localization in breast cancer.
Topics: Alendronate; Amines; Animals; Breast Neoplasms; Chickens; Feasibility Studies; Female; Ferric Compou | 2013 |
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial | 2013 |
Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis.
Topics: Adenosine; Adenosine Triphosphate; Alendronate; Animals; Apyrase; Bone Density Conservation Agents; | 2015 |
Randomized clinical trials and observational studies are more often alike than unlike.
Topics: Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imi | 2014 |
Bisphosphonates do not reduce breast cancer in postmenopausal women.
Topics: Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imi | 2015 |
In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis.
Topics: Alendronate; Animals; Antimetabolites, Antineoplastic; Bone Density Conservation Agents; Bone Neopla | 2015 |
Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment.
Topics: Alendronate; Alkaline Phosphatase; Anastrozole; Animals; Aromatase Inhibitors; Bone Density; Bone De | 2017 |
Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection.
Topics: Alendronate; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Division; Ce | 2009 |
Oral bisphosphonate use and breast cancer incidence in postmenopausal women.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosp | 2010 |
[Jaw osteonecrosis induced by oral biphosphonates: 12 cases].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alendronate; Autoimmu | 2010 |
Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
Topics: Alendronate; Animals; Apoptosis; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms | 2011 |
Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Dip | 2010 |
Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Etidronic Aci | 2010 |
A multimodal magnetic resonance imaging nanoplatform for cancer theranostics.
Topics: Alendronate; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Contrast Media; Dru | 2011 |
Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model.
Topics: Acrylamides; Alendronate; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bone Neoplasms; B | 2011 |
Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Alendronate; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Death; | 2012 |
Awareness and education of patients receiving bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Arthralgia; Bisphosphonate-Associated Os | 2012 |
Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bon | 2012 |
Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; | 2012 |
Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Boronic Acids; Bortezom | 2012 |
A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Coh | 2012 |
Early discontinuation of treatment for osteoporosis.
Topics: Alendronate; Bone Diseases, Metabolic; Breast Neoplasms; California; Cohort Studies; Estrogen Replac | 2003 |
Testing an intervention for preventing osteoporosis in postmenopausal breast cancer survivors.
Topics: Adult; Aged; Alendronate; Bone Density; Breast Neoplasms; Calcium; Combined Modality Therapy; Contra | 2003 |
Bisphosphonates decrease telomerase activity and hTERT expression in MCF-7 breast cancer cells.
Topics: Alendronate; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Clodronic Acid; | 2005 |
Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Alendronate; Antineoplastic Combined Chemoth | 2005 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breas | 2005 |
Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis?
Topics: Aged; Alendronate; Analysis of Variance; Bone Density; Bone Density Conservation Agents; Bone Diseas | 2005 |
Differential effects of bisphosphonates on breast cancer cell lines.
Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cycl | 2007 |
Bisphosphonates may also be effective in the management of non-skeletal metastases in hormone receptor positive breast cancer.
Topics: Alendronate; Breast Neoplasms; Diphosphonates; Female; Humans; Neoplasm Metastasis; Receptors, Estro | 2007 |
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fem | 2007 |
Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Cos | 2007 |
Amino-bisphosphonates decrease hTERT gene expression in breast cancer in vitro.
Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Clodronic Acid; Diphospho | 2007 |
Contrast agent may aid cancer detection.
Topics: Alendronate; Breast Neoplasms; Contrast Media; Humans; Tomography, Optical | 2007 |
Bisphosphonates: are they standard of care for the treatment of breast cancer?
Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Fem | 2007 |
Oral bisphosphonate associated osteonecrosis of the jaws: three case reports.
Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Bo | 2007 |
Contradictory hormone studies renew debate over breast cancer link.
Topics: Adult; Age Factors; Alendronate; Breast Neoplasms; Case-Control Studies; Coronary Disease; Diphospho | 1995 |
Prevention of osteoporosis in women treated for hereditary breast and ovarian carcinoma: a need that is overlooked.
Topics: Adult; Alendronate; Breast Neoplasms; Calcitonin; Diet; Diphosphonates; Exercise Therapy; Female; Hu | 1998 |
Skin reactions associated with bisphosphonates: a report of 3 cases and an approach to management.
Topics: Adult; Alendronate; Antineoplastic Agents; Breast Neoplasms; Clodronic Acid; Diphosphonates; Drug Hy | 1998 |
[A study of the safety of rapid infusion of alendronate].
Topics: Alendronate; Blood Urea Nitrogen; Bone Neoplasms; Breast Neoplasms; Calcium; Drug Administration Sch | 1999 |
Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women.
Topics: Alendronate; Bone Density; Breast Neoplasms; Coronary Disease; Decision Support Techniques; Estrogen | 1999 |
[Effective alendronate therapy against a bone metastasis occurring during docetaxel therapy for breast cancer--a case report].
Topics: Aged; Alendronate; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Docetaxel; F | 1999 |
[Pain relief with alendronate therapy in a breast cancer patient with bone metastasis].
Topics: Aged; Alendronate; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Ne | 2000 |
Drugs for prevention and treatment of postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Resorption; Breast Neoplasms; Calciton | 2000 |
Managing menopause after breast cancer: balancing risks and benefits.
Topics: Adult; Alendronate; Antidepressive Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Calcit | 2001 |
A 60-year-old woman trying to discontinue hormone replacement therapy.
Topics: Alendronate; Breast Neoplasms; Contraindications; Coronary Disease; Decision Making; Estrogen Replac | 2002 |